NIH royalties
From Conservapedia
This is an old revision of this page, as edited by Aschlafly (Talk | contribs) at 00:58, April 11, 2022. It may differ significantly from current revision.
NIH royalties on its patents can enrich the bureaucracy and its officers.
Since 2017, the royalty income has been declining, which have increased the pressure at the NIH to push for patentable patents rather than inexpensive medications for treating COVID-19.[1]